EA202090108A1 - Применение церебролизина - Google Patents

Применение церебролизина

Info

Publication number
EA202090108A1
EA202090108A1 EA202090108A EA202090108A EA202090108A1 EA 202090108 A1 EA202090108 A1 EA 202090108A1 EA 202090108 A EA202090108 A EA 202090108A EA 202090108 A EA202090108 A EA 202090108A EA 202090108 A1 EA202090108 A1 EA 202090108A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cerebrolysine
application
cerebrolysin
cadasil
leukoencephalopathy
Prior art date
Application number
EA202090108A
Other languages
English (en)
Inventor
Штефан Винтер
Херберт Мёсслер
Original Assignee
Эвер Нейро Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эвер Нейро Фарма Гмбх filed Critical Эвер Нейро Фарма Гмбх
Publication of EA202090108A1 publication Critical patent/EA202090108A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)

Abstract

Настоящее изобретение относится к церебролизину для применения в снижении смертности пациентов с CADASIL (церебральной аутосомно-доминантной артериопатией с субкортикальными инфарктами и лейкоэнцефалопатией).
EA202090108A 2017-08-28 2018-08-28 Применение церебролизина EA202090108A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin
PCT/EP2018/073106 WO2019042983A1 (en) 2017-08-28 2018-08-28 USE OF CERBROLYSINE

Publications (1)

Publication Number Publication Date
EA202090108A1 true EA202090108A1 (ru) 2020-03-31

Family

ID=59745228

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090108A EA202090108A1 (ru) 2017-08-28 2018-08-28 Применение церебролизина

Country Status (13)

Country Link
US (1) US20200376040A1 (ru)
EP (2) EP3449931B1 (ru)
JP (1) JP7281450B2 (ru)
CN (1) CN111050780B (ru)
AU (1) AU2018326339A1 (ru)
CA (1) CA3073991A1 (ru)
EA (1) EA202090108A1 (ru)
ES (2) ES2767070T3 (ru)
HR (1) HRP20200031T1 (ru)
MX (1) MX2020002267A (ru)
PH (1) PH12020500376A1 (ru)
PL (2) PL3449931T3 (ru)
WO (1) WO2019042983A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220168325A1 (en) * 2019-03-25 2022-06-02 The University Of Vermont Methods to promote cerebral blood flow in the brain
ES2964145T3 (es) 2020-07-13 2024-04-04 Ever Neuro Pharma Gmbh Método para producir un hidrolizado de proteína de cerebro de mamífero
WO2022256396A1 (en) * 2021-06-02 2022-12-08 Regeneron Pharmaceuticals, Inc. Treatment of cerebrovascular disease with neurogenic locus notch homolog protein 3 (notch3) agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0452299B1 (en) 1990-04-12 1997-06-18 EBEWE Arzneimittel Gesellschaft mbH Use of a mixture of peptides and amino acids in the prophylaxis or treatment of dementia
WO2010022193A2 (en) * 2008-08-20 2010-02-25 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates

Also Published As

Publication number Publication date
ES2901508T3 (es) 2022-03-22
KR20200045503A (ko) 2020-05-04
HRP20200031T1 (hr) 2020-03-20
EP3449931B1 (en) 2019-10-16
CA3073991A1 (en) 2019-03-07
PH12020500376A1 (en) 2020-12-07
AU2018326339A1 (en) 2020-03-05
EP3675879A1 (en) 2020-07-08
JP7281450B2 (ja) 2023-05-25
EP3449931A1 (en) 2019-03-06
WO2019042983A1 (en) 2019-03-07
ES2767070T3 (es) 2020-06-16
JP2020531568A (ja) 2020-11-05
CN111050780B (zh) 2023-11-03
PL3449931T3 (pl) 2020-06-01
CN111050780A (zh) 2020-04-21
EP3675879B1 (en) 2021-09-15
PL3675879T3 (pl) 2022-02-14
MX2020002267A (es) 2020-10-22
US20200376040A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
EA202090655A1 (ru) Комбинированные терапевтические средства и их применение
EA201691607A1 (ru) Микроорганоиды и способы их получения и применения
BR112017006664A2 (pt) terapias de combinação
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2021010528A (es) Metodos y composiciones para el tratamiento de las ulceras.
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EA201690456A1 (ru) Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201891468A1 (ru) Композиции и способы для снижения экспрессии tau
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
EA202090108A1 (ru) Применение церебролизина
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
EA201792281A1 (ru) Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4- метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.